Search - tctmd.com

Displaying 161 - 180 of 279

Sort: Relevancy | Date

COVID-19: TCTMD’s Dispatch for November Week 2

News Daily News

COVID-19: TCTMD’s Dispatch for November Week 2

November 08, 2021

Myocarditis After COVID-19 Vaccine: Data ‘Reassure’ More and More

News Conference News TCT 2021

Myocarditis After COVID-19 Vaccine: Data ‘Reassure’ More and More

November 04, 2021

Myocarditis After Covid-19 Vaccination: What Clinicians Need to Know

Presentation TCT 2021

Myocarditis After Covid-19 Vaccination: What Clinicians Need to Know

Presenter: Guy Witberg

November 04, 2021

Impact of the COVID-19 Pandemic on FDA: Review of Changes and Looking Ahead

Presentation TCT 2021

Impact of the COVID-19 Pandemic on FDA: Review of Changes and Looking Ahead

Presenter: William Maisel

November 04, 2021

TCTMD’s Top 10 Most Popular Stories for October 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for October 2021

November 02, 2021

COVID-19: TCTMD’s Dispatch for November Week 1

News Daily News

COVID-19: TCTMD’s Dispatch for November Week 1

November 01, 2021

November 2021 News Roundup

News Opinion CV Team Dispatch

November 2021 News Roundup

November 01, 2021

STEMI and COVID-19 Often a Lethal Combo, Affirms Largest Study Yet

News Daily News

STEMI and COVID-19 Often a Lethal Combo, Affirms Largest Study Yet

October 29, 2021

COVID-19: TCTMD’s Dispatch for October Week 4

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 4

October 25, 2021

AHA Policy Statement Focuses on Gaps in STEMI Systems of Care

News Daily News

AHA Policy Statement Focuses on Gaps in STEMI Systems of Care

October 18, 2021

COVID-19: TCTMD’s Dispatch for October Week 3

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 3

October 18, 2021

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

News Daily News

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

October 15, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

HF Care Didn’t Suffer as Clinicians Turned to Telehealth in COVID-19

News Daily News

HF Care Didn’t Suffer as Clinicians Turned to Telehealth in COVID-19

October 13, 2021

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

News Daily News

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Yael L. Maxwell

October 12, 2021

COVID-19: TCTMD’s Dispatch for October Week 2

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 2

October 11, 2021

Studies Highlight Rarity of Myocarditis With mRNA COVID-19 Vaccines

News Daily News

Studies Highlight Rarity of Myocarditis With mRNA COVID-19 Vaccines

October 06, 2021

COVID-19: TCTMD’s Dispatch for October Week 1

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 1

October 04, 2021

VALVENOR Study Helps Clarify Risks in Moderate AS Patients

News Daily News

VALVENOR Study Helps Clarify Risks in Moderate AS Patients

October 01, 2021

TCTMD’s Top 10 Most Popular Stories for September 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2021

October 01, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.